Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting triple-negative breast cancers with the Smac-mimetic birinapant.
Lalaoui N, Merino D, Giner G, Vaillant F, Chau D, Liu L, Kratina T, Pal B, Whittle JR, Etemadi N, Berthelet J, Gräsel J, Hall C, Ritchie ME, Ernst M, Smyth GK, Vaux DL, Visvader JE, Lindeman GJ, Silke J. Lalaoui N, et al. Among authors: merino d. Cell Death Differ. 2020 Oct;27(10):2768-2780. doi: 10.1038/s41418-020-0541-0. Epub 2020 Apr 27. Cell Death Differ. 2020. PMID: 32341449 Free PMC article.
TRAIL in cancer therapy: present and future challenges.
Mérino D, Lalaoui N, Morizot A, Solary E, Micheau O. Mérino D, et al. Expert Opin Ther Targets. 2007 Oct;11(10):1299-314. doi: 10.1517/14728222.11.10.1299. Expert Opin Ther Targets. 2007. PMID: 17907960 Free PMC article. Review.
Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.
Morizot A, Mérino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, Lanneau D, Bouyer F, Solary E, Chauffert B, Saas P, Garrido C, Micheau O. Morizot A, et al. Among authors: merino d. Cell Death Differ. 2011 Apr;18(4):700-11. doi: 10.1038/cdd.2010.144. Epub 2010 Nov 12. Cell Death Differ. 2011. PMID: 21072058 Free PMC article.
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, Maragno AL, Chanrion M, Schneider E, Pal B, Li X, Dewson G, Gräsel J, Liu K, Lalaoui N, Segal D, Herold MJ, Huang DCS, Smyth GK, Geneste O, Lessene G, Visvader JE, Lindeman GJ. Merino D, et al. Sci Transl Med. 2017 Aug 2;9(401):eaam7049. doi: 10.1126/scitranslmed.aam7049. Sci Transl Med. 2017. PMID: 28768804
280 results